NeuroPointDX ASD Test
Autism Spectrum Disorder Diagnosis
DevelopmentActive
Key Facts
Indication
Autism Spectrum Disorder Diagnosis
Phase
Development
Status
Active
Company
About Stemina Biomarker Discovery
Stemina Biomarker Discovery, founded in 2007 and based in Madison, Wisconsin, is a pioneer in human cell-based toxicology testing. The company's core technology is a metabolomics platform applied to human pluripotent stem cell-derived models, which powers its flagship assays for developmental toxicity (devTOX quickPredict) and cardiotoxicity (Cardio quickPredict). These assays provide faster, cheaper, and human-relevant safety data for pharmaceutical, chemical, and consumer product companies, positioning Stemina at the forefront of the New Approach Methodologies (NAMs) movement. The company also has a diagnostic arm, NeuroPointDX, focused on developing metabolomic tests for autism spectrum disorder.
View full company profile